December 13, 2021 11:46:16
- Lexaria Bioscience plans to launch approximately 12 applied research and development programs in 2022
- The programs are designed to explore the ability of the company’s patented DehydraTECH(TM) to improve drug delivery processes for multiple indications
- Research will continue into the use of DehydraTECH-CBD for high blood pressure, as well as the technology’s potential for oral nicotine delivery
Diabetes, rheumatoid disease, Alzheimer’s Disease, and estrogen delivery, are some of the multiple indications that drug delivery platform innovator
Lexaria Bioscience (NASDAQ: LEXX) is planning to target with its research and development programs next year. The markets targeted provide multiple opportunities for success and are now expected to reach an overall estimated value of more than $160 billion annually, worldwide over the next few years.
The company will conduct pharmacokinetic and efficacy modelling studies to determine if its patented DehydraTECH(TM) technology can be used successfully to improve delivery of drugs or active pharmaceutical…
Read More>>
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at
https://cnw.fm/LEXX
About CBDWire
CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2)
CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.
Receive Text Alerts from CBDWire:
Text “Cannabis” to 21000
For more information please visit
https://www.cbdwire.com and or
https://CBDWire.News
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published:
https://CBDWire.com/Disclaimer
CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
[email protected]